» Articles » PMID: 38682806

Automated CT Quantification of Interstitial Lung Abnormality in Patients with Resectable Stage I Non-small Cell Lung Cancer: Prognostic Significance

Overview
Journal Thorac Cancer
Date 2024 Apr 29
PMID 38682806
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In patients with non-small cell lung cancer (NSCLC), interstitial lung abnormalities (ILA) have been linked to mortality and can be identified on computed tomography (CT) scans. In the present study we aimed to evaluate the predictive value of automatically quantified ILA based on the Fleischner Society definition in patients with stage I NSCLC.

Methods: We retrospectively reviewed 948 patients with pathological stage I NSCLC who underwent pulmonary resection between April 2009 and October 2022. A commercially available deep learning-based automated quantification program for ILA was used to evaluate the preoperative CT data. The Fleischner Society definition, quantitative results, and interdisciplinary discussion led to the division of patients into normal and ILA groups. The sum of the fibrotic and nonfibrotic ILA components constituted the total ILA component and more than 5%.

Results: Of the 948 patients with stage I NSCLC, 99 (10.4%) patients had ILA. Shorter overall survival and recurrence-free survival was associated with the presence of ILA. After controlling for confounding variables, the presence of ILA remained significant for increased risk of death (hazard ratio [HR] = 3.09; 95% confidence interval [CI]: 1.91-5.00; p < 0.001) and the presence of ILA remained significant for increased recurrence (HR = 1.96; 95% CI: 1.16-3.30; p = 0.012).

Conclusions: The automated CT quantification of ILA, based on the Fleischner Society definition, was significantly linked to poorer survival and recurrence in patients with stage I NSCLC.

Citing Articles

Automated CT quantification of interstitial lung abnormality in patients with resectable stage I non-small cell lung cancer: Prognostic significance.

Chung J, Park J, Kim D Thorac Cancer. 2024; 15(16):1305-1311.

PMID: 38682806 PMC: 11147660. DOI: 10.1111/1759-7714.15306.

References
1.
Hatabu H, Hunninghake G, Richeldi L, Brown K, Wells A, Remy-Jardin M . Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med. 2020; 8(7):726-737. PMC: 7970441. DOI: 10.1016/S2213-2600(20)30168-5. View

2.
Axelsson G, Putman R, Aspelund T, Gudmundsson E, Hida T, Araki T . The associations of interstitial lung abnormalities with cancer diagnoses and mortality. Eur Respir J. 2020; 56(6). PMC: 7876778. DOI: 10.1183/13993003.02154-2019. View

3.
Putman R, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M . Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA. 2016; 315(7):672-81. PMC: 4828973. DOI: 10.1001/jama.2016.0518. View

4.
Brown S, Padilla M, Mhango G, Powell C, Salvatore M, Henschke C . Interstitial Lung Abnormalities and Lung Cancer Risk in the National Lung Screening Trial. Chest. 2019; 156(6):1195-1203. DOI: 10.1016/j.chest.2019.06.041. View

5.
Iwasawa T, Okudela K, Takemura T, Fukuda T, Matsushita S, Baba T . Computer-aided Quantification of Pulmonary Fibrosis in Patients with Lung Cancer: Relationship to Disease-free Survival. Radiology. 2019; 292(2):489-498. DOI: 10.1148/radiol.2019182466. View